Evidence map›Paper›PMID 42711292›Full record

ArticleNature communications2026

Design of a live-attenuated bacterial vaccine using effector network engineering.

Sarah Jordan, Priyanka Biswas, Maria L Alberdi, Jake Samuel, Zuza Kozic, Rita Berkachy, Vishwas Mishra, Nazila Kamaly, Oscar Ces, Jyoti Choudhary and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sarah JordanDepartment of Life Sciences, Imperial College London, London, UK.
Priyanka BiswasDepartment of Life Sciences, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-1932-2352
Maria L AlberdiDepartment of Life Sciences, Imperial College London, London, UK.
Jake SamuelDepartment of Chemistry, Imperial College London, London, UK.
Zuza KozicFunctional Proteomics Group, Chester Beatty Laboratories, Institute of Cancer Research, London, UK.
Rita BerkachyDepartment of Life Sciences, Imperial College London, London, UK.
Vishwas MishraDepartment of Life Sciences, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-7069-4613
Nazila KamalyDepartment of Chemistry, Imperial College London, London, UK.
Oscar CesDepartment of Chemistry, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-6418-5644
Jyoti ChoudharyFunctional Proteomics Group, Chester Beatty Laboratories, Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-0881-5477
Julia Sanchez-GarridoDepartment of Life Sciences, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-5847-4167
Abigail ClementsDepartment of Life Sciences, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-2285-777X
Gad FrankelDepartment of Life Sciences, Imperial College London, London, UK. g.frankel@imperial.ac.uk.ORCID http://orcid.org/0000-0002-0046-1363

Funding

Wellcome TrustWellcome Trust (Wellcome) 224282/Z/21/Z
6 · The paper itself

Abstract

Enteropathogenic Escherichia coli (EPEC) and Citrobacter rodentium (CR) are extracellular enteric attaching and effacing (A/E) pathogens of humans and mice, respectively. Their virulence relies on intimate bacterial attachment and a network of type III secretion system effectors. Here, through systematic reduction and redesign of the effector network in CR, we develop an attenuated strain, CRV (CR Vaccine), encoding a subset of ten effectors. CRV colonises C57BL/6 mice ~100-fold lower than wild type CR (CR

Indexed as

Bacterial VaccinesCitrobacter rodentiumEnterobacteriaceae InfectionsEnteropathogenic Escherichia coliEscherichia coli InfectionsAnimalsAntibodies, BacterialAntigens, BacterialEscherichia coli ProteinsFemaleHumansMiceMice, Inbred C3HMice, Inbred C57BLVaccines, AttenuatedVirulenceAntibodies, BacterialAntigens, BacterialBacterial VaccinesEscherichia coli ProteinsVaccines, AttenuatedVirulence Factors

Identifiers

PMID42711292
PMCPMC13554080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.